Pfizer cancer drug hits BioPlus’ shelves
ALTAMONTE SPRINGS, Fla. — A specialty pharmacy provider has begun selling a drug made by Pfizer for treating kidney cancer.
The company announced that it had launched Inlyta (axitinib), which the Food and Drug Administration approved last month for treating renal cell carcinoma in patients with advanced disease for whom first-line systemic therapy has failed. According to the American Cancer Society, 60,000 people in the United States are diagnosed with the disease each year, and 13,000 die.
"BioPlus has extensive expertise in launching cancer therapy medications, and we are thrilled to be in the select group with access to this limited drug that offers hope to patients with RCC," BioPlus director of pharmaceutical contracting Sharon Ferrer said.
Pfizer granted another specialty provider, Phoenix-based The Apothecary Shops, distribution rights for Inlyta earlier this month.
Fougera names SVP commercial operations
MELVILLE, N.Y. — Fougera Pharmaceuticals has promoted Walt Kaczmarek to serve as the company’s SVP commercial operations, the drug maker announced.
Kaczmarek, who joined the company in 2004, has been managing national accounts for Fougera’s three marketing divisions, including Fougera, PharmaDerm, and Savage Labs, for the past eight years. He recently began managing accounts for the managed care markets of Fougera’s branded division PharmaDerm, Fougera said.
”Walt has been an integral part of the steady growth of Fougera Pharmaceuticals,” said David Klaum, SVP, general manager at Fougera. “Walt has demonstrated his dedication to this company and its customers, and I am confident that he’ll continue to play a key role in our pursuit of increased business opportunities.”
More diagnoses to drive celiac disease market growth through decade
LONDON — The global market for celiac disease is expected to grow substantially over the decade as more people are diagnosed with the condition, according to a new report.
The report, by British market research firm GlobalData, found that the global celiac disease therapeutics market would be worth more than $512 million by 2017 and $664.4 million by 2019.
The firm noted that while people with celiac disease can treat it with a gluten-free diet, such diets are relatively expensive, limit nutritional variety and often restrict social activities, thus creating a significant unmet need for nondietary therapies.
The current drug pipeline is weak, the firm said, with no drugs in phase-3 clinical trials and only two in phase-2 trials that may not enter the market until later in the decade.